Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Cytochrome P450 (CYP) & UGT Inhibition/Induction In Vitro DMPK Service
Are you currently facing long drug development cycles, difficulty in predicting clinical outcomes, or challenges in assessing drug-drug interaction risks? Our Non-Human Primate CYP & UGT Inhibition/Induction In Vitro DMPK Assays help you streamline preclinical development and reduce translational risks. Leveraging our advanced in vitro models and extensive NHP resources, we provide crucial data on ADME properties and DDI potential, giving you the clarity and confidence to move your program forward.
Introduction to NHP CYP & UGT In Vitro DMPK Services
Drug metabolism is the cornerstone of pharmacokinetics, and a drug's metabolic fate is a primary determinant of its safety and efficacy. Our NHP in vitro DMPK assays provide a critical bridge between preclinical models and human clinical trials, focusing on two pivotal enzyme families: Cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). These enzymes are responsible for the vast majority of Phase I and Phase II metabolic reactions, respectively. By studying their inhibition and induction potential, we can accurately predict how your compound will interact with other drugs and how its metabolism will be affected.
What Our Service Is
We measure the potential of a new chemical entity to either inhibit or induce the activity of critical NHP CYP and UGT enzymes, which provides invaluable data for predicting human drug-drug interactions (DDIs).
- Early-stage lead optimization: Screen promising compounds to deselect those with high DDI risk, focusing resources on the best candidates.
- Translational research: Use NHP models to generate data that more closely mirrors human metabolism than data from rodent models, ensuring more accurate predictions.
Why Choose Us?
- The unpredictability of drug behavior from animal models to humans-Our use of NHP models, which share high genetic and physiological similarity to humans, provides more clinically translatable data. This reduces the risk of late-stage failures and saves significant time and cost.
- The complex and time-consuming process of DDI risk assessment-Our specialized assays streamline the DDI evaluation process, providing clear, actionable data that accelerates your regulatory timeline and provides confidence in your compound's safety profile.
Fig.1 Schematic diagram of NHP CYP & UGT in vitro DMPK services.
Key Benefits of Our Service
Our service is built on a foundation of scientific rigor, operational excellence, and unparalleled resources, offering a distinct advantage.
- Exceptional Response Speed: We are committed to providing prompt and efficient communication from the moment of your inquiry, ensuring rapid project initiation and timely delivery of results.
- Extensive NHP Resources: Our access to a diverse range of NHP biologicals, including fresh hepatocytes, liver microsomes, and S9 fractions from various species, ensures that we can select the most appropriate model for your specific compound, leading to more relevant and reliable data.
- Comprehensive Customization: Every drug development program is unique. We offer a high degree of flexibility to customize protocols, including enzyme panel selection, compound concentrations, and time points, to perfectly match your project's specific requirements.
- In-Depth Reporting: Our final reports go beyond raw data. They include detailed methodologies, comprehensive data analysis, and expert interpretation to help you understand the full implications of the results. We integrate published data and our proprietary knowledge to provide a robust context for your findings.
How Creative Biolabs' Assays Can Assist Your Project?
We provide a streamlined and transparent process to help you get the essential data you need to make informed decisions. Our approach is grounded in reality, providing tangible deliverables and clear problem-solving capabilities.
Workflow
01
Required Starting Materials
02
Initial Consultation & Study Design
03
Sample Preparation & Incubation
04
Analysis via LC-MS/MS
05
Data Analysis & Interpretation
06
Report Generation
Key Deliverables
Upon project completion, you will receive a comprehensive package of deliverables designed for clarity and regulatory readiness:
- Detailed Lab Report: A professional, written report including the study's purpose, detailed methodology, materials used, and a clear summary of the results.
- Raw and Processed Data: All raw data files from the LC-MS/MS analysis, along with processed data tables and statistical analyses.
- Expert Analysis and Interpretation: Our findings are presented with contextual insights, including the determined Ki or fold-induction values, and a professional assessment of the DDI risk.
- Model Annotations: Detailed information on the specific NHP models and enzyme panels used in the assays.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 compounds
- Typical Turnaround Time (TAT): 10-15 business days
- Assay Pass Rate: >98%
Our Valued Partners
Frequently Asked Questions
Q: Why should I choose NHP models over more common rodent models for these assays?
A: That's a great question! While rodent models are useful for initial screening, NHP models are genetically and physiologically closer to humans. This means the data on drug metabolism, particularly for complex enzymes like P450s and UGTs, is far more predictive of what you'll see in a clinical trial. Using NHP models can significantly reduce the risk of a compound failing in later, more expensive clinical stages.
Q: How do you differentiate between enzyme inhibition and induction?
A: Excellent question. Inhibition is when a compound decreases the activity of a drug-metabolizing enzyme, which can lead to a dangerous buildup of other co-administered drugs. Induction is the opposite—a compound increases the enzyme's activity, which can lead to other drugs being cleared too quickly, reducing their therapeutic effect. Our assays are specifically designed to test for both possibilities, providing a full picture of your compound's DDI potential.
Q: My compound is primarily metabolized by UGTs. Can your assays accommodate this?
A: Absolutely. While many focus on P450s, we recognize that UGTs are equally critical for many therapeutics. Our services are fully equipped to assess the inhibition and induction of key UGT isoforms, providing a comprehensive metabolic profile for your compound.
Q: How do you ensure the data you provide is reliable and accurate?
A: We understand that data integrity is paramount. Our assays are conducted in a controlled, quality-assured environment using validated protocols. We use state-of-the-art analytical equipment and rigorous quality control measures to ensure that every data point is precise and reproducible.
Q: How do I get started with your NHP DMPK services?
A: It's very easy! Simply click on the link below to reach out to our team. We'll set up a consultation to discuss your specific needs, answer any remaining questions, and provide a detailed quote tailored to your project. We're here to help you succeed!
Contact Us
Creative Biolabs serves as your reliable collaborator for NHP in vitro DMPK assays. Our proficiency in P450 and UGT inhibition/induction, paired with our dedication to delivering high-quality, clinically pertinent data, empowers you to confidently expedite your drug development program. Contact our team for further details and to discuss your project needs.